COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

  • STATUS
    Recruiting
  • participants needed
    80
  • sponsor
    University of Pennsylvania
Send
Updated on 5 August 2020
See if I qualify
ct scan
x-rays
pneumonia
covid-19
chest x-ray
SARS
acute respiratory syndrome (sars)

Summary

The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.

Description

This open-label, randomized, controlled, phase 1 trial will assess the safety and efficacy of convalescent plasma in severely ill, hospitalized participants with pneumonia due to COVID-19. This study will enroll adults 18 years old and older, including pregnant women.

A total of 80 eligible participants will be randomized to receive either 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 and standard of care (treatment arm) or standard of care alone (control arm). Participants in the treatment arm will receive 2 units of convalescent plasma on Study Day 1 in addition to standard of care.

Participants will be assessed on study Day 1 (pre-dose), 30 minutes after each unit of plasma, on all Study Days while hospitalized, and Study Days 15, 22, 29, and 60. All participants will undergo a series of safety and efficacy, assessments. Blood samples will be collected on Days 1 (prior to plasma administration), 3, 8, 15, 29, and 60. Oropharyngeal or endotracheal samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, and 15.

Details
Condition Covid 19
Age 18years - 100years
Treatment COVID-19 convalescent plasma
Clinical Study IdentifierNCT04397757
SponsorUniversity of Pennsylvania
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Adult 18 years of age
Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment
Note - An exception must be requested to the Sponsor if 72 hours since
positive test
\. Hospitalized in participating facility
\. Documentation of pneumonia with radiographic evidence of infiltrates by
imaging (e.g., chest x-ray or CT scan)
\. Abnormal respiratory status that is judged worse than baseline by the
investigator and as documented at any point within 24 hours prior to
randomization, consistent with ordinal scale levels 5, 6 or 7, specifically
defined as
Room air saturation of oxygen (SaO2) < 93%, OR
Requiring supplemental oxygen, OR
Tachypnea with respiratory rate 30 6\. Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements

Exclusion Criteria

Contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator
Clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than COVID-19
Receipt of other investigational therapy as a part of another clinical trial. Note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan
x-rays
pneumonia
covid-19
chest x-ray
SARS
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.